Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Large Growth in Short Interest

Alzamend Neuro, Inc. (NASDAQ:ALZN) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 74,300 shares, a growth of 130.7% from the December 31st total of 32,200 shares. Based on an average daily volume of 137,100 shares, the days-to-cover ratio is currently 0.5 days. Approximately 1.4% of the company’s shares are short sold.

Alzamend Neuro Stock Up 1.8 %

NASDAQ:ALZN traded up $0.02 during trading hours on Thursday, hitting $1.14. The stock had a trading volume of 80,216 shares, compared to its average volume of 93,247. The business’s 50 day moving average is $1.20 and its 200-day moving average is $1.88. Alzamend Neuro has a one year low of $1.06 and a one year high of $15.06.

Alzamend Neuro (NASDAQ:ALZN) last issued its quarterly earnings data on Wednesday, December 11th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($2.38) by $1.98. Analysts forecast that Alzamend Neuro will post -1.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets cut their target price on Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating on the stock in a research note on Monday, December 16th.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.